Fundamental Analysis of OncoCyte Corp - Growth / Value Index
OCX - Valuation Highlights
Valuation Analysis
Price to Book Ratio is 0.422 indicating that it is undervalued.
Tsr Value Index - Poor Score of 20.31
Book Value in last 3 years is trending down
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | -0.213 | -0.395 | -65.63 % | |
| Price to Book | 0.426 | 0.876 | 99.52 % | 0.864 |
| Price to Sales | -6.92 | 15.32 | -15.55 % | |
| Enterprise Value to EBITDA Multiple | -0.469 | -0.252 | -360.13 % |
OCX - Profitability Highlights
Profitability Analysis
During the past twelve months, the company has given a strong Net Margin of 3241.89%
Tsr Profitability Index - Very Poor Score of 5.00
Very Low Dividend Yield of 0 %
Negative Net profit for last two years
Company Net profit is Negative for last 5 Quarters
In the last three years, the company has given poor Returns on Equity
In the last three years, the company has given poor Returns on Assets
Negative Net Margin MRQ
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | -216.69 | -221.80 | -4.33 % | -62.48 |
| Return On Asset | -85.54 | -75.80 | -4.07 % | -21.35 |
| Net Profit Margin | 3241.89 | -3880.18 | 49.01 % | -5092.99 |
| Operating Profit Margin | 431.91 | -1598.77 | 14.90 % | -1591.72 |
| EBITDA Margin | 2764.89 | -3700.21 | -91.25 % | -1591.72 |
Highlights
| Market Cap | 39158.28 K |
| Enterprise Value | 30391.28 K |
| Price/Book TTM | 0.426 |
| Outstanding Share | 13364.60 K |
| Float/ Outstanding Share | 26.61% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 0 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 3.00 |
| Altman Z Score | -7.33 |
| Sloan Ratio | -0.379 |
| Peter Lynch Fair Value | 0 |
OCX - Growth Highlights
Growth Analysis
STRONG JUMP IN NET SALE : YoY growth
Tsr Growth Index - Very Poor Score of 17.66
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | -2344.00 K | 52.71 % | 26.81 % |
| Gross Profit | 2428.00 K | 2894.44 % | 138.31 % |
| EBITDA | -64809.00 K | 192.06 % | 23.26 % |
| Net Profit | -75990.00 K | 22.13 % | 139.15 % |
| EPS | -13.73 | 39.63 % | NA |
OCX - Stability Highlights
Stability Analysis
Tsr Stability Index - Poor Score of 26.56
Altman Z Score of -7.33 suggest high risk
Company is unable to generate enough free cash to support the business.
Interest Coverage of -1091.67
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.0260 | 9.32 % | 0.0260 |
| Cash Ratio | 1.31 | -20.61 % | |
| Quick Ratio | 0 | 0 % | 1.47 |
| Shareholders Equity | 34.17 | -0.252 % | |
| Debt to EBITDA | -0.0123 | 72.06 % |
Historical Valuation Ratios of OncoCyte Corp
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of OncoCyte Corp
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of OncoCyte Corp
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of OncoCyte Corp
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)